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The COVID pandemic in 2020 had unpredictable consequences on the presentation
and management of patients with ischaemic heart disease. Subsequent to these ini-
tial responses the impact of the initial pandemic can be reviewed and responses can
be considered. It is clear that there are new opportunities for optimising patient
management pathways and in particular enhanced use of information technology.
Changes in attitudes towards health and perceived risk are evident within both the
catheter lab teams and our patient cohorts. Summating both the intellectual and
emotional experiences of the pandemic are essential to prepare for either a second
wave of COVID 19 or any new pandemic threat in the future.
The initial impact of coronavirus disease
2019
The initial impact of the coronavirus disease 2019
(COVID-19) pandemic within Europe began in Italy and these
initial events have been well documented. Hospitals in
northern Italy were flooded with cases of patients present-
ing with COVID-19-related symptoms and unfortunately,
their local hospital services were unable to cope.1 This led
to doctors being unable to treat their patients optimally
and pictures on the television news of patients lying in corri-
dors. Italian doctors were interviewed reflecting on a lack
of capacity and provision for patients and their lack of per-
sonal protective equipment (PPE). These news reports sent
a shudder throughout healthcare systems worldwide. It was
clear from an early stage that many patients with heart dis-
ease appeared to preferentially suffer more serious conse-
quences from COVID-19 infection and that cardiac
involvementwas a common consequence of COVID-19 infec-
tion.2–4 Presentation with symptoms and signs suggestive of
acute ST-segment elevation myocardial infarction (STEMI)
was rumoured to be frequent and catastrophic.5
As the virus began to progress initially through Spain, UK,
and the rest of Europe, European interventional cardiolo-
gists found themselves preparing their services for these
new challenges.6 There was considerable confusion about
the level of PPE that was required to treat patients with
COVID-19 infection safely. The consequences of ‘aerosol
generation’ in patients with acute infection were and are
considered to be a crucial part of disease transmission
within hospitals. Concern about the management of car-
diac arrest with the requirement for cardiac resuscitation
was raised as it was clear that patients presenting as an
emergency could not be screened by nasal swabbing
or a computed tomography (CT) scan to exclude active
COVID-19 infection.
The discussion revealed that concern about cardiac ar-
rest had already resulted in some services in China regress
to delivery of thrombolysis as the initial management
choice rather than mechanical treatment for patients with
STEMI.7 In many countries, official initial advice was con-
tradictory about optimal protection for the catheterization
laboratory (Cath lab) teams varying from standard sterility
measures (single gown, single gloves, and standard surgical
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mask) to Level 3 PPE used to treat patients suffering from
Ebola virus (double gown, double gloves, face visor with ei-
ther an MP3 mask or ventilator). A significant lack of avail-
ability of PPE contributed to the confusion and increasing
anxiety within hospitals. Ultimately, however, by late
March 2020, most interventional cardiology services had
made their local preparations and braced themselves for
the expected onslaught.6
What happened next was unexpected. Governments
throughout Europe had initiated draconian lockdownmeas-
ures to reduce case to case transmission within the commu-
nity. Vivid images from Italy had made it evident to
everyone within society that hospital services were at risk
of collapse and explicit advice was given ‘to stay away
from hospitals unless it was absolutely necessary’. It was
also clear to individuals that the most likely place to catch
COVID-19 was within a hospital. The consequences of these
dire warnings lead to dramatic and sustained reductions in
presentation of patients to hospitals including patients
with chest pain. The worrisome avoidance of medical care
led to a substantial reduction of STEMI presentations which
ranged from 20% to 50% during COVID-19 outbreak,
associated with a greater decline of non-ST-segment
elevation myocardial infarction (NSTEMI), as outlined in
Table 1.8–14 Furthermore, this reduction in health-seeking
behaviour has been well established by Wilson et al.,8
who demonstrated a three-fold increase of late-
presenters patients with STEMI during the pandemic pe-
riod. Besides these different temporal trends, a global
reduction of primary percutaneous coronary intervention
(PCI) rate for STEMI patients was documented up to43%
with respect to non-pandemic period (Table 1). Cardiac
Cath lab services that had cancelled all elective work
and been stripped down to expect a tsunami of emer-
gency cases found themselves unoccupied for the first
time in living memory.15
The second phase of the COVID-19 crisis:
‘the new normal’
By May 2020, it had become clear that hospitals we are not
going to be overwhelmed in most European cities. Many
interventional cardiac services had accommodated and
developed and moved into a phase that was coined ‘the
new normal’.16 Although there were considerable numbers
of patients with COVID-19 within hospitals, societal lock-
down measures, and enhanced hospital provision had
avoided a collapse of healthcare services. Urgent and
emergency patients with coronary disease started to re-
emerge along with cases of ‘missed heart attack’ present-
ing with mechanical complications,17 such as ventricular
septal rupture or acute ischaemic mitral regurgitation.
Review of these patients’ histories confirmed that patients
had remained at home with chest pain during the ‘eye of
the storm’ and had only come to hospital when they could
bear their symptoms no longer.
The consequences of the change inmanagement/clinical
priorities were evident in particular areas. Firstly, there
was a lack of availability of ventilators and intensive care.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































elective surgical cases were effectively not possible and
some stable patients were deferred. For those patients
who needed urgent treatment and could not be deferred,
interventional percutaneous options were pursued includ-
ing multivessel coronary stenting18 and/or percutaneous
aortic valve implant. Discussion of individualized manage-
ment strategies for these patients also required a new ap-
proach. Face to face meeting for multidisciplinary teams
(MDTs) was advised against because of the risk of cross in-
fection19 and many heart teams began using computer
technology including Microsoft Teams and Zoom. It soon be-
came clear that these new IT platforms had a number of
potential advantages especially the ability to allow ready
viewing of angiographic, echocardiographic, and CT images
in a universal format.
Treatment of patients presenting with acute myocardial
infarction was made more complex by wearing the en-
hanced PPE. Wearing an extra gown and a visor together
with lead coat protection resulted in inevitable perspira-
tion with subsequent clouding of glasses and/or visors. This
made viewing the angiographic screens difficult and conse-
quently many operators chose to try and complete emer-
gency cases as quickly and safely as possible. Once the
culprit lesion treatment was complete, many operators
favoured deferring non-culprit lesions and there was prob-
ably less acute use of intracoronary imaging. For patients
presenting with acute coronary syndromes (ACS), some
centres increased their use of non-invasive imaging in par-
ticular CTscanning. Reducing the duration of inpatient stay
was an important priority both to clear beds for other
patients and also to reduce the chances of patients con-
tacting COVID-19 whilst an inpatient.
Many hospitals also had to review and change their meth-
ods of patient follow-up. It was simply not possible to bring
patients to the outpatient department within the hospital
both because of the challenge of travel but, in particular,
the need for social distancing which reduced outpatient ca-
pacity. The use of telemedicine became almost routine
overnight with telephone consultations and, in particular,
computer-enhanced virtual consultations demonstrating
immediate efficacy. Using the virtual clinic, a clinician
could still undertake clinical review in a timely way with
clear logistic advantages for clinicians/hospitals together
with time savings in travel for patients.20 One of the inter-
esting consequences of these changes in the consultation
environment and circumstances may have been a tendency
towards more conservative medical therapy. Recent publi-
cation of the ISCHEMIA trial had suggested that revasculari-
zation in asymptomatic patients was probably of less
benefit than many clinicians had predicted.21 These data
together with a reluctance to admit patients to hospital
probably contributed to a reduction in elective
revascularization.
Initial reflections on the COVID-19 pandemic
and future impacts?
It is not yet possible to predict whether the onset of winter
together with the recrudescence of winter flu and COVID-
19 will herald a similar healthcare catastrophe in 2020–21.
The potential availability of vaccines could have a pro-
found impact and this together with society’s attitude and
tolerance of social distancing will presumably reduce the
rates of virus transmission and subsequent clinical infection
with COVID-19. However, it is possible to provide some ini-
tial reflections on the extraordinary preceding 6–9months
and perhaps speculate about some of the longer term con-
sequences with relevance to the management of patients
with coronary disease and our interventional cardiac prac-
tises (Figure 1).
(1) Healthcare systems must be prepared for future
pandemics. Clear specific advice about how to limit
in-hospital transmission and protect healthcare
staff is crucial and within the cardiac Cath lab, this
means more availability of appropriate PPE that
can be worn comfortably without compromising
practice.6,22 It is particularly noteworthy that this
pandemic has highlighted the personal healthcare
risks that Cath lab teams take.22 The risks of radia-
tion exposure have probably been chronically
under-emphasized and the risk of blood–borne vi-
ruses has almost been completely forgotten in
many labs. An enhanced emphasis on protection of
the Cath lab team is apparent and overdue. In the
future, this might provide an opportunity for ro-
botic and/or enhanced protective computer tech-
nology. Using current robotic technology even
complex chronic occlusions can be treated by an
operator controlling the wires and catheters seated
at a joystick. Other team members are also pro-
tected from radiation as during the operative radia-
tion screening, they are not required to be standing
at the Cath lab table.
(2) Patients perceptions of risk have certainly been
influenced by this crisis. There is a new acute
awareness of the hazards associated with hospital
admission and any hospital procedure. Hospital ac-
quired infection has been a problem for many years
particularly when it is associated with prostheses,
but this has probably been downplayed and mini-
mized. It seems likely that patients will have an en-
hanced awareness of the potential downsides of
any procedures and that careful consent before
embarking upon any interventional procedure will
be even more important than ever.23 These chang-
ing attitudes are likely to impact PCI practice. It is
possible that patients may choose to persist with
medical management when angina is manageable
or minimal and for some patients with more com-
plex disease coronary artery bypass surgery may no
longer be appealing. Careful physiological assess-
ment using pressure wire to determine which
lesions need treatment may allow complete revas-
cularization using coronary stents as an alternative.
Data from the Syntax 2 trial are encouraging in this
regard.24 The predictability of procedures is proba-
bly at the heart of this debate and in this regard op-
timization of stent deployment is of critical
importance. In more complex patients, the pres-
ence of potentially restrictive calcification


















































































enhances the need for intracoronary imaging.
Ensuring that ischaemia has been abolished or at
least minimized in the culprit territory by the com-
pletion of the interventional coronary procedure
must surely be a clear objective. Although this
seems an obvious expectation, it is not as predict-
able as many interventional cardiologists believe
and further research and practise development are
required to ensure this basic goal.
(3) The use of virtual conferencing technology may be
one of the most obvious benefits of the pandemic
to our clinical practises.19 There is little doubt that
the MDT/heart team can work extremely effec-
tively in this virtual environment. It allows en-
hanced discussion between interventional
cardiologists and cardiac surgeons both within the
same hospital and perhaps more importantly be-
tween hospitals. It seems an achievable goal that
personalized revascularization approaches opti-
mally utilizing local expertise can result from this
enhanced timely discussion. In many healthcare
systems, there are unacceptable delays and long in-
patient stays for ACS patients with angiographic ev-
idence of multivessel disease. There are delays
occur, while optimal management strategies are
considered and then for subsequent transfer to be
performed. Ensuring these delays are minimized by
early discussion and/or completing preoperative as-
sessment locally is likely to be of clear benefit to
the patient and the hospitals.
(4) Using computer and mobile phone technology for
patient consultation has the potential for consider-
able patient and economic benefit.20 Virtual con-
sultation can be time effective for the provider but
importantly facilitate the patient’s participation in
their care.22 This could be evident in simple fac-
tors, such as enhanced drug compliance but also po-
tentially participation in PROMS (patient recorded
outcome measures), clinical trials, and audit data
collection. When one considers the potential of this
technology, the historic standard of a follow-up in a
clinic looks prosaic.
(5) Reducing the variability of care for interventional
patients and increasing consistency of the approach
to revascularization has been discussed for many
years. Discussions between cardiac surgeons and in-
terventional cardiologists about patients with mul-
tivessel coronary disease have occasionally been
heated especially when it is considered that some
patients might be better treated with multiple
Figure 1 Future practices of percutaneous coronary intervention after COVID-19 outbreak. ED, emergency departments; PPE, personal protective
equipment; PROMS, patient-recorded outcome measures.


















































































stents rather than surgery. The provision of mean-
ingful and respected international guidelines has an
important role, but artificial intelligence and ma-
chine learning have huge potential. The ability of
artificial intelligence to more accurately assess
which of the observed coronary lesions are causing
ischaemia and predict the outcome of revasculari-
zation is likely to become the standard in the fu-
ture. It seems likely that CT scanning will become
ubiquitous for patients with stable symptoms and
experience during COVID-19 suggests more poten-
tial for CT in ACS too. Enhanced diagnostics before
arriving in the Cath lab together with an agreed in-
terventional management plan has the potential to
reduce practice variability considerably. Most im-
portantly, it may improve outcomes and then pa-
tient satisfaction, but it is also very likely to reduce
cost.
(6) Finally, the COVID-19 crisis has also impacted dra-
matically on medical education within interven-
tional practice, shedding lights on the potential of
social media, such as Twitter.25 On-line conferences
have become the new standard and international
conference travel has been minimal. It remains to
be seen whether traditional ‘pilgrimages’ to large
Congresses will re-emerge in 2021. If they do, one
suspects that it will be with enhanced respect and
understanding of the crucial role that friendship
and interactive discussion has in the shared experi-
ence of professional life within interventional cardi-
ology. Whether this can be duplicated by chatting
on a computer screen has yet to be proven!
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